Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-107309
Filing Date
2025-08-12
Accepted
2025-08-12 16:09:49
Documents
61
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-20250630.htm   iXBRL 10-Q 2832673
2 EX-10.2 fate-ex10_2.htm EX-10.2 49647
3 EX-31.1 fate-ex31_1.htm EX-31.1 12822
4 EX-32.1 fate-ex32_1.htm EX-32.1 8597
  Complete submission text file 0000950170-25-107309.txt   12234043

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fate-20250630.xsd EX-101.SCH 1324917
64 EXTRACTED XBRL INSTANCE DOCUMENT fate-20250630_htm.xml XML 2930625
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 251206752
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)